TY - JOUR
T1 - Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome
T2 - A retrospective case-control study
AU - Jabbour, Elias
AU - Mathisen, Michael S.
AU - Garcia-Manero, Guillermo
AU - Champlin, Richard
AU - Popat, Uday
AU - Khouri, Issa
AU - Giralt, Sergio
AU - Kadia, Tapan
AU - Chen, Julianne
AU - Pierce, Sherry
AU - Koca, Ebru
AU - Daver, Naval
AU - Tanaka, Maria
AU - Rondon, Gabriela
AU - Oran, Betul
AU - Parmar, Simrit
AU - Kantarjian, Hagop
AU - de Lima, Marcos
PY - 2013/3
Y1 - 2013/3
N2 - Allogeneic stem cell transplantation (allo-SCT) is the only potentially curative treatment for myelodysplastic syndrome (MDS). Recently, hypomethylating agents (HMAs) have been shown to improve survival in patients with high-risk MDS. We conducted a retrospective case-control study to compare survival with these treatment modalities in patients with untreated MDS. Controls were identified using a departmental database and transplant patients were matched in at least three of the following five criteria: year of diagnosis, age, blast percentage, International Prognostic Scoring System cytogenetic risk, and time from diagnosis to treatment. Median overall survival (OS) was 26 and 25 months for, respectively, allo-SCT [(n = 53); range, 2-210 months] and HMA [(n = 40); range, 2-98 months] (P = 0.89). Four-year survival rates were 24 and 23% for allo-SCT patients and the nontransplant cohort, respectively. Patients undergoing allo-SCT after 2000 had longer median OS compared with those transplanted before 2000 (41 versus 7 months, P=0.001). These results would suggest that prospective studies are needed to delineate the timing and efficacy of allo-SCT in the HMA era.
AB - Allogeneic stem cell transplantation (allo-SCT) is the only potentially curative treatment for myelodysplastic syndrome (MDS). Recently, hypomethylating agents (HMAs) have been shown to improve survival in patients with high-risk MDS. We conducted a retrospective case-control study to compare survival with these treatment modalities in patients with untreated MDS. Controls were identified using a departmental database and transplant patients were matched in at least three of the following five criteria: year of diagnosis, age, blast percentage, International Prognostic Scoring System cytogenetic risk, and time from diagnosis to treatment. Median overall survival (OS) was 26 and 25 months for, respectively, allo-SCT [(n = 53); range, 2-210 months] and HMA [(n = 40); range, 2-98 months] (P = 0.89). Four-year survival rates were 24 and 23% for allo-SCT patients and the nontransplant cohort, respectively. Patients undergoing allo-SCT after 2000 had longer median OS compared with those transplanted before 2000 (41 versus 7 months, P=0.001). These results would suggest that prospective studies are needed to delineate the timing and efficacy of allo-SCT in the HMA era.
UR - http://www.scopus.com/inward/record.url?scp=84874343368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874343368&partnerID=8YFLogxK
U2 - 10.1002/ajh.23371
DO - 10.1002/ajh.23371
M3 - Article
C2 - 23345254
AN - SCOPUS:84874343368
SN - 0361-8609
VL - 88
SP - 198
EP - 200
JO - American journal of hematology
JF - American journal of hematology
IS - 3
ER -